OrthoPediatrics (KIDS) Projected to Post Quarterly Earnings on Wednesday

OrthoPediatrics (NASDAQ:KIDS) is expected to be releasing its Q1 2025 earnings data after the market closes on Wednesday, May 7th. Analysts expect OrthoPediatrics to post earnings of ($0.38) per share and revenue of $51.68 million for the quarter. OrthoPediatrics has set its FY 2025 guidance at EPS.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The business had revenue of $52.67 million during the quarter, compared to analyst estimates of $51.16 million. During the same quarter in the previous year, the business earned ($0.23) EPS. On average, analysts expect OrthoPediatrics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

OrthoPediatrics Trading Down 1.0 %

Shares of KIDS stock opened at $21.55 on Wednesday. The business’s 50 day moving average is $23.38 and its two-hundred day moving average is $24.38. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19. OrthoPediatrics has a 12 month low of $20.25 and a 12 month high of $35.99. The company has a market cap of $523.38 million, a PE ratio of -17.52 and a beta of 1.17.

Insider Activity at OrthoPediatrics

In related news, insider Gregory A. Odle sold 5,359 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $133,224.74. Following the completion of the transaction, the insider now directly owns 148,788 shares in the company, valued at approximately $3,698,869.68. This represents a 3.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO David R. Bailey sold 6,620 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $164,573.20. Following the completion of the transaction, the chief executive officer now owns 319,155 shares of the company’s stock, valued at $7,934,193.30. The trade was a 2.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,732 shares of company stock worth $589,978. 31.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on KIDS. Needham & Company LLC reaffirmed a “buy” rating and issued a $42.00 target price on shares of OrthoPediatrics in a report on Wednesday, April 9th. Lake Street Capital began coverage on shares of OrthoPediatrics in a research note on Monday, April 7th. They set a “buy” rating and a $37.00 target price for the company. Stifel Nicolaus decreased their price target on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, March 5th. Finally, Truist Financial cut their price objective on shares of OrthoPediatrics from $26.00 to $24.00 and set a “hold” rating for the company in a research report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.00.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.